On the other hand, a decrease in the use of antimalarials (61.9–25.9%), antivirals (50–9.35%), tocilizumab (9.52–1.44%), and other anti-SIRS, especially interferon beta (26.19–1.44%) was observed (Supplementary Materials Table S2 and Figure 2). This evidence concerns the gene IFNB1 and systemic inflammatory response syndrome.